Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03289650
Other study ID # STU00205327
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 5, 2017
Est. completion date February 23, 2021

Study information

Verified date March 2023
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of the study is to prospectively investigate the impact of two maintenance calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and twice-daily tacrolimus on subpopulations of T and B cells and alloreactive T cells as well as on renal allograft function.


Description:

Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. Lifelong immunosuppressive therapies are required to prevent organ rejection. However, long term exposure to immunosuppressive therapy after kidney transplantation can place patients at risk for multiple adverse events. The optimal immunosuppressive therapy is not well established. Tacrolimus, a calcineurin inhibitor (CNI) is highly effective in preventing acute rejection after organ transplantation (2). It is used as part of the immunosuppression regimen for the majority of kidney and liver transplant recipients (3). However, treatment with current formulation of Tacrolimus generates high peaks and low troughs in drug concentrations in the blood. It is known that high exposure to CNI is associated with renal toxicities and adverse events (4). New once-daily dosage formulations are now developed with the hope of minimizing side effects while maintaining excellent outcomes (5-8). LCP-Tacro (EnvarsusĀ® XR, Veloxis Pharmaceuticals), a new once-daily formulation of tacrolimus, was approved by the FDA in 2015 for conversion from twice-daily tacrolimus in kidney transplant recipients. It is a prolonged-release tacrolimus formulation, utilizing a MeltDose drug delivery technology designed to improve the bioavailability of drugs with low water solubility (1). Recent clinical data demonstrated that once-daily LCP-Tacro has improved pharmacokinetic bioavailability, rapid achievement of therapeutic trough levels, less fluctuation and swing in whole blood concentration, non-inferior efficacy and similar safety, with lower tacrolimus dose than other tacrolimus formulations. The target population is adult recipients of immediately functioning living and deceased donor renal allografts. Immediate function will be defined as the absence of the need for hemodialysis in the first week following renal transplantation. Prospective randomized single center open label study of 2 groups of kidney transplant patients - Group 1 : standard of care (SOC) control group will receive tacrolimus twice-daily (n=25) - Group 2 : LCP-Tacro (EnvarsusĀ® XR) group will receive LCPT tablets once daily (n=25)


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date February 23, 2021
Est. primary completion date February 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patients who are males or females aged 18-65 years. 2. Use of the following induction medications: basiliximab and rituximab. 2. Donors aged 18-65 years. 3. No prior organ transplant 4. Patients who are single-organ recipients (kidney only). 5. Women who are of childbearing potential must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of contraception throughout the treatment period. 6. Subject (recipient) is able to understand the consent form and give written informed consent Exclusion Criteria: 1. Delayed graft function (please see above). 2. Known sensitivity or contraindication to alemtuzumab, EnvarsusĀ® XR, tacrolimus or MMF. 3. Use of the following induction medications: basiliximab and rituximab 4. Patient with significant or active infection. 5. Patients with a positive flow cytometric crossmatch using donor lymphocytes and recipient serum. 6. Patients with PRA > 40% 7. Patients with current or historic donor specific antibodies 8. Body Mass Index (BMI) of < 18 or > 35 9. Patients who are pregnant or nursing mothers. 10. Patients whose life expectancy is severely limited by diseases other than renal disease. 11. Ongoing active substance abuse, drug or alcohol. 12. Major ongoing psychiatric illness or recent history of noncompliance. 13. Significant cardiovascular disease (e.g.): - Significant non-correctable coronary artery disease; - Ejection fraction below 30%; - History of recent myocardial infarction. 14. Malignancy within 3 years, excluding non-melanoma skin cancers. 15. Serologic evidence of infection with HIV or HBVs-Ag positive. 16. Patients with a screening/baseline total white blood cell count < 4,000/mm3; platelet count < 100,000/mm3; triglyceride > 400 mg/dl; total cholesterol > 300 mg/dl. 17. Investigational drug within 30 days prior to transplant surgery. 18. Anti-T cell therapy within 30 days prior to transplant surgery. 19. Diagnosis of atypical-Hemolytic Uremic Syndrome (aHUS). 20. Subjects transplanted with a Hepatitis C NAT-positive kidney.

Study Design


Intervention

Drug:
Tacrolimus
immunosuppressive agent tacrolimus, given twice-daily
Tacrolimus Extended Release Oral Tablet [Envarsus]
immunosuppressive agent extended-release tacrolimus, given once daily

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Lorenzo Gallon

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant change in the mean eGFR from the baseline (2 weeks post transplant), 3 months (post transplant) , and 12 months (post transplant). 2 weeks post transplant through 12 months post transplant
Secondary Change in Subpopulations of T Cells From 2 Weeks Post Transplant Through 12 Months Post Transplant Blood, urine and kidney tissue analysis via serial flow cytometric immunophenotyping (includes regulatory T and B cell populations as well as immune functions). Measured at 2 weeks post transplant, 3 months post transplant, 12 months post transplant
Secondary Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant Acute rejection of kidney transplant is determined via biopsy. Measured at 3 months post transplant, 12 months post transplant
Secondary Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant Graft loss is determined via biopsy. Measured at 3 months post transplant, 12 months post transplant
Secondary Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant Subject survival status is continually monitored via routine follow-up visits. Through 12 months post transplant
Secondary Number of Participants With Change in Allograft Immunohistopathology Profile Tissue analysis via immunohistopathological staining and microscopic examination Moderate acute tubular necrosis => presence of focal coagulative necrosis or infarction on histopathologic examination
Arteriolar hyalinosis grade 2 means: Replacement of degenerated smooth muscle cells by hyaline deposits in more than 1 arteriole, without circumferential involvement
Global glomerulosclerosis >grade 2, means glomerulosclerosis affecting more than 50% of glomeruli in the biopsy sample
IFTA : Interstitial fibrosis and tubular atrophy: Inflammation in 26% to 50% of scarred cortical parenchyma
Measured at 3 months post transplant, 12 months post transplant
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Completed NCT01178216 - Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation Phase 1/Phase 2